Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Vitamin D3 Supplementation Has No Effect on Conventional Cardiovascular Risk Factors: A Parallel-Group, Double-Blind, Placebo-Controlled RCT

Vitamin D3 Supplementation Has No Effect on Conventional Cardiovascular Risk Factors: A... AbstractContext:Observational studies show an association between low vitamin D status assessed by circulating 25-hydroxyvitamin D and cardiovascular events and mortality. Data from randomized controlled trials are limited.Objective:The aim of this study was to test whether daily doses of vitamin D3 at 400 or 1000 IU/d for 1 yr affected conventional markers of cardiovascular disease (CVD) risk.Design:We conducted a parallel-group, double-blind, placebo-controlled randomized controlled trial. Randomization was computer generated. Participants and study investigators were blinded to intervention groupings throughout the trial.Setting:The study was conducted at the Clinical Research Facility, University of Aberdeen, United Kingdom.Participants:A total of 305 healthy postmenopausal women aged 60–70 yr were recruited for the study.Intervention:Each woman received a daily capsule of 400 or 1000 IU vitamin D3 or placebo randomly allocated.Main Outcome Measures:Primary outcomes were serum lipid profile [total, high-density lipoprotein, and low-density lipoprotein cholesterol; triglycerides; and apolipoproteins A-1 and B100], insulin resistance (homeostatic model assessment), inflammatory biomarkers (high-sensitivity C-reactive protein, IL-6, soluble intracellular adhesion molecule-1), and blood pressure.Results:A total of 265 (87%) participants completed all study visits. Small differences between groups for serum apolipoprotein B100 change [repeated measures ANOVA, P = 0.04; mean (sd), −1.0 (10.0) mg/dl (400 IU); −1.0 (10.0) mg/dl (1000 IU); and +0.02 (10.0) mg/dl (placebo)] were not considered clinically significant. Other systemic markers for CVD risk remained unchanged. There was significant seasonal variation in systolic and diastolic blood pressure independent of vitamin D dose (P < 0.001, linear mixed model). Mean (sd) reduction in systolic blood pressure from winter to summer was −6.6 (10.8) mm Hg.Conclusions:Improving vitamin D status through dietary supplementation is unlikely to reduce CVD risk factors. Confounding of seasonality should be recognized and addressed in future studies of vitamin D. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Journal of Clinical Endocrinology & Metabolism Oxford University Press

Vitamin D3 Supplementation Has No Effect on Conventional Cardiovascular Risk Factors: A Parallel-Group, Double-Blind, Placebo-Controlled RCT

Download PDF
12 pages

Loading next page...
 
/lp/oxford-university-press/vitamin-d3-supplementation-has-no-effect-on-conventional-pkC2pP6pMN

References (41)

Publisher
Oxford University Press
Copyright
Copyright © 2012 by The Endocrine Society
ISSN
0021-972X
eISSN
1945-7197
DOI
10.1210/jc.2012-2126
pmid
22865902
Publisher site
See Article on Publisher Site

Abstract

AbstractContext:Observational studies show an association between low vitamin D status assessed by circulating 25-hydroxyvitamin D and cardiovascular events and mortality. Data from randomized controlled trials are limited.Objective:The aim of this study was to test whether daily doses of vitamin D3 at 400 or 1000 IU/d for 1 yr affected conventional markers of cardiovascular disease (CVD) risk.Design:We conducted a parallel-group, double-blind, placebo-controlled randomized controlled trial. Randomization was computer generated. Participants and study investigators were blinded to intervention groupings throughout the trial.Setting:The study was conducted at the Clinical Research Facility, University of Aberdeen, United Kingdom.Participants:A total of 305 healthy postmenopausal women aged 60–70 yr were recruited for the study.Intervention:Each woman received a daily capsule of 400 or 1000 IU vitamin D3 or placebo randomly allocated.Main Outcome Measures:Primary outcomes were serum lipid profile [total, high-density lipoprotein, and low-density lipoprotein cholesterol; triglycerides; and apolipoproteins A-1 and B100], insulin resistance (homeostatic model assessment), inflammatory biomarkers (high-sensitivity C-reactive protein, IL-6, soluble intracellular adhesion molecule-1), and blood pressure.Results:A total of 265 (87%) participants completed all study visits. Small differences between groups for serum apolipoprotein B100 change [repeated measures ANOVA, P = 0.04; mean (sd), −1.0 (10.0) mg/dl (400 IU); −1.0 (10.0) mg/dl (1000 IU); and +0.02 (10.0) mg/dl (placebo)] were not considered clinically significant. Other systemic markers for CVD risk remained unchanged. There was significant seasonal variation in systolic and diastolic blood pressure independent of vitamin D dose (P < 0.001, linear mixed model). Mean (sd) reduction in systolic blood pressure from winter to summer was −6.6 (10.8) mm Hg.Conclusions:Improving vitamin D status through dietary supplementation is unlikely to reduce CVD risk factors. Confounding of seasonality should be recognized and addressed in future studies of vitamin D.

Journal

The Journal of Clinical Endocrinology & Metabolism – Oxford University Press

Published: Oct 1, 2012

There are no references for this article.